A Spanish study found that nirsevimab prophylaxis significantly reduced infant hospitalizations, ICU admissions, and severe ...

Pfizer's maternal vaccine, sold as Abrysvo, and Sanofi and AstraZeneca's antibody shot, Beyfortus, are available in the ...

New Zealand has the world's highest rates of serious illness caused by RSV, with 2000 children under five admitted to ...

By Dennis Thompson HealthDay ReporterTUESDAY, May 6, 2025 (HealthDay News) -- Newborns can be effectively protected against ...

For a broader group of infants—0 to 7 months old—RSV-NET showed a 43 percent drop in hospitalizations in the 2024–2025 RSV season, and NVSN saw a 28 percent drop. Again, when Houston was excluded from ...

Here's what RSV is, why it especially impacts the youngest and oldest members of society and how it is usually treated.

Nirsevimab, a monoclonal antibody, is highly effective in real-world conditions at preventing severe respiratory syncytial ...

A  scientific forum held in HCM City on April 27 announced a pioneering preventive method to help prevent lower respiratory ...

A meta-analysis indicates that the monoclonal antibody nirsevimab offers significant real-world protection against severe ...

The seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring ...